Patents by Inventor Wei Dang

Wei Dang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220386172
    Abstract: A user equipment (UE) configured for dual connectivity with a split bearer configuration may transmit uplink data packets to one or both a master cell group (MCG) and a secondary cell group (SCG). The UE may transmit an uplink transmission from a packet data convergence protocol (PDCP) entity over one or both of a first radio link control (RLC) entity associated with the MCG and a second RLC entity associated with the SCG. The configuration including a transmit buffer threshold. The UE may receive, at the PDCP entity, an uplink switch start indication. The UE may activate the second RLC entity in response to receiving the uplink switch start indication. The UE may transmit a buffer status report according to a current transmit buffer level plus the transmit buffer threshold. Accordingly, the UE may communicate with the SCG based on the uplink switch start indication.
    Type: Application
    Filed: November 25, 2019
    Publication date: December 1, 2022
    Inventors: Ling XIE, Qingxin CHEN, Reza SHAHIDI, Jun HU, Sivaram Srivenkata PALAKODETY, Vishal DALMIYA, Wei-Jei SONG, Arnaud MEYLAN, Zhibin DANG, Karthikeyan SABAPATHI
  • Patent number: 11506387
    Abstract: A low-pollution combustor and a combustion control method therefor. The low-pollution combustor includes a combustor head including a primary combustion stage and a precombustion stage, the primary combustion stage including a primary-combustion-stage channel and a primary-combustion-stage swirler disposed in the primary-combustion-stage channel. The primary combustion stage includes a pre-film plate disposed in the primary-combustion-stage channel, and the pre-film plate is radially divided into an outer-layer pre-film plate and an inner-layer pre-film plate.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: November 22, 2022
    Assignee: AECC COMMERCIAL AIRCRAFT ENGINE CO., LTD.
    Inventors: Longfei Dang, Pei He, Wei Chen, Rong Xu, Yajia E, Pan Chen, Mingming Su, Hao Chen
  • Publication number: 20220356166
    Abstract: Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.
    Type: Application
    Filed: February 5, 2021
    Publication date: November 10, 2022
    Inventors: Pravin L. Kotian, Yarlagadda S. Babu, Weihe Zhang, Peng-Cheng Lu, Minwan Wu, Wei Lv, Trung Xuan Nguyen, Zhao Dang, Venkat R. Chintareddy, V. Satish Kumar, Krishnan Raman
  • Publication number: 20220348804
    Abstract: A composite polyester hot-melt adhesive, a preparation method thereof and a preparation method of an anti-scouring geotextile are provided. The preparation method of the composite polyester hot-melt adhesive includes the following steps: performing an esterification reaction on a dibasic acid and a dihydric alcohol under a protection of nitrogen and an action of a titanium/cobalt composite catalyst, adding a stabilizer for a polycondensation reaction to obtain a polyester hot-melt adhesive, then adding polymethyl methacrylate (PMMA) microspheres for mixing and stirring to obtain the composite polyester hot-melt adhesive. The anti-scouring geotextile is obtained by bonding a polyethylene terephthalate woven fabric with a polypropylene geotextile by the composite polyester hot-melt adhesive.
    Type: Application
    Filed: July 4, 2020
    Publication date: November 3, 2022
    Applicant: China Institute of Water Resources and Hydropower Research
    Inventors: Shu YU, Zuyu CHEN, Laizhang ZHANG, Wenxin YANG, Yanfeng WEN, Zhanbin LI, Wei CAO, Maosheng ZHANG, Fan YUE, Yanlong LI, Peng LI, Zheng SI, Wugang GAO, Pengyi LIU, Weiqin DANG, Zongjun HAN, Jiawei ZHOU, Qiang XUE, Qiang ZHANG, Aiping WANG, Yumei GUO, Xiaowei LIANG, Xueying LIU
  • Patent number: 11416043
    Abstract: A display motherboard includes a motherboard body, wherein n recess structures for guiding the motherboard body to fracture are provided on a surface of the motherboard body, n being greater than 1; wherein the n recess structures are arranged in sequence and centers of the n recess structures are collinear.
    Type: Grant
    Filed: March 27, 2020
    Date of Patent: August 16, 2022
    Assignees: CHENGDU BOE OPTOELECTRONICS TECHNOLOGY CO., LTD., BOE TECHNOLOGY GROUP CO., LTD.
    Inventors: Ming Yang, Wei Wang, Bin Liu, Keheng Li, Yang Dang, Shaojie Qin
  • Publication number: 20220235044
    Abstract: The invention discloses a method for synthesizing 1,7-naphthyridine derivatives, which relates to the technical field of synthesizing pharmaceutical intermediates and organic chemical intermediates, wherein the method includes: (1) 2-chloro-3-amino-pyridine being used as Compound I as a starting material, and protecting an amino group to prepare Compound II; (2) the Compound II reacting with an aldehydation reagent under alkaline conditions to obtain Compound III; (3) cyclizing the Compound III with acrylate compounds under the action of Lewis acid to prepare compound IV.
    Type: Application
    Filed: November 17, 2020
    Publication date: July 28, 2022
    Inventors: Wei QIAN, Yuhua SHI, Xing HUANG, Changming DONG, Junkui DANG, Zhipeng WANG, Yu FENG, Hong XU, Zongxi HUANG, Ye CHEN, Huafei SHEN, Jun ZHANG
  • Patent number: 11370774
    Abstract: Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.
    Type: Grant
    Filed: March 16, 2021
    Date of Patent: June 28, 2022
    Assignee: BioCryst Pharmaceuticals, Inc.
    Inventors: Pravin L. Kotian, Yarlagadda S. Babu, Weihe Zhang, Peng-Cheng Lu, Minwan Wu, Wei Lv, Trung Xuan Nguyen, Zhao Dang, Venkat R. Chintareddy, V. Satish Kumar, Krishnan Raman
  • Patent number: 11254746
    Abstract: An anti-human PD-1 monoclonal antibody, and a preparation method therefor and an application thereof. The anti-human PD-1 monoclonal antibody has good bioactivity, can effectively bind with an extracellular region of a human PD-1 protein receptor, and can effectively seal PD-1 protein at protein level and cellular level and block the binding of the PD-1 protein with a ligand PD-L1, thereby effectively enhancing immunity. The monoclonal antibody can be applied independently or jointly with other antitumor drugs to tumor immunotherapy and the diagnosis and screening of patients with PD-L1 positive tumors; and the monoclonal antibody has a promising prospect in the preparation of drugs for treating tumors, resisting autoimmune diseases and the like.
    Type: Grant
    Filed: January 22, 2018
    Date of Patent: February 22, 2022
    Assignee: SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LT
    Inventors: Jie Zhao, Honghai Gao, Jinlin Guo, Wei Dang, Lingqiao Zhu, Chenghai Zhang, Le Zhao, Jianhe Chen, Haomin Huang, Zhenping Zhu
  • Publication number: 20210139600
    Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Application
    Filed: July 29, 2020
    Publication date: May 13, 2021
    Inventors: Gregory Lazar, Wei Dang, John Desjarlais, Sher Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
  • Publication number: 20200377597
    Abstract: An anti-human PD-1 monoclonal antibody, and a preparation method therefor and an application thereof. The anti-human PD-1 monoclonal antibody has good bioactivity, can effectively bind with an extracellular region of a human PD-1 protein receptor, and can effectively seal PD-1 protein at protein level and cellular level and block the binding of the PD-1 protein with a ligand PD-L1, thereby effectively enhancing immunity. The monoclonal antibody can be applied independently or jointly with other antitumor drugs to tumor immunotherapy and the diagnosis and screening of patients with PD-L1 positive tumors; and the monoclonal antibody has a promising prospect in the preparation of drugs for treating tumors, resisting autoimmune diseases and the like.
    Type: Application
    Filed: January 22, 2018
    Publication date: December 3, 2020
    Inventors: Jie Zhao, Honghai Gao, Jinlin Guo, Wei Dang, Lingqiao Zhu, Chenghai Zhang, Le Zhao, Jianhe Chen, Haomin Huang, Zhenping Zhu
  • Patent number: 10738112
    Abstract: An anti-human IL-17A monoclonal antibody, the preparation method, and the use thereof are provided. The anti-human IL-17A monoclonal antibody can specifically bind to human IL-17A and has a good effect for inhibiting the secretion of inflammatory cytokines, such as IL-6 and the like by means of various cell lines induced by IL-17A, and can be used for preparing drugs for treating diseases involving immune-medicated inflammatory responses.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: August 11, 2020
    Assignee: SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD.
    Inventors: Chenghai Zhang, Lingqiao Zhu, Jinlin Guo, Jie Zhao, Honghai Gao, Lin Ma, Wei Dang, Yan Yang
  • Patent number: 10584176
    Abstract: The present invention relates to Fc variants having increased affinity for Fc?RIIc, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: March 10, 2020
    Assignee: Xencor, Inc.
    Inventors: Gregory Lazar, Wei Dang, John Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes
  • Patent number: 10563495
    Abstract: Disclosed herewith a separation device for performing phase separation on a three-phase liquid. The device includes: a housing; at least one pair of longitudinal baffle plates; a flow channel formed between every pair of longitudinal baffle plates; and collection chambers formed between adjacent pairs of longitudinal baffle plates. Each collection chamber is provided with a transverse baffle plate to separate the collection chamber into a first phase and a second phase collection cells. Each flow channel is provided with multiple lateral baffle plates to separate the flow channel into multiple sub-channels. In the areas of each longitudinal baffle plate where the first phase and second phase collection cells are located respectively, said longitudinal baffle plate is provided with a first and a second phase guiding holes in communication with the first phase and the second collection cells respectively.
    Type: Grant
    Filed: August 15, 2018
    Date of Patent: February 18, 2020
    Assignees: CHINA PETROLEUM & CHEMICAL CORPORATION, SINOPEC EXPLORATION & PRODUCTION RESEARCH INSTITUTE
    Inventors: Changchao Hu, Wei Dang, Xiaoxuan Xu, Zhiwei Tang, Lili Wang, Wenjie Tan, Pengyuan Ding, Caixia Bi, Youlin Zheng
  • Publication number: 20190161544
    Abstract: An anti-human IL-17A monoclonal antibody, the preparation method, and the use thereof are provided. The anti-human IL-17A monoclonal antibody can specifically bind to human IL-17A and has a good effect for inhibiting the secretion of inflammatory cytokines, such as IL-6 and the like by means of various cell lines induced by IL-17A, and can be used for preparing drugs for treating diseases involving immune-medicated inflammatory responses.
    Type: Application
    Filed: June 9, 2017
    Publication date: May 30, 2019
    Inventors: Chenghai ZHANG, Lingqiao ZHU, Jinlin GUO, Jie ZHAO, Honghai GAO, Lin MA, Wei DANG, Yan YANG
  • Publication number: 20190071512
    Abstract: The present invention relates to Fc variants having increased affinity for Fc?RIIc, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Application
    Filed: September 21, 2018
    Publication date: March 7, 2019
    Inventors: Gregory Lazar, Wei Dang, John Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes
  • Publication number: 20190055829
    Abstract: Disclosed herewith a separation device for performing phase separation on a three-phase liquid. The device includes: a housing; at least one pair of longitudinal baffle plates; a flow channel formed between every pair of longitudinal baffle plates; and collection chambers formed between adjacent pairs of longitudinal baffle plates. Each collection chamber is provided with a transverse baffle plate to separate the collection chamber into a first phase and a second phase collection cells. Each flow channel is provided with multiple lateral baffle plates to separate the flow channel into multiple sub-channels. In the areas of each longitudinal baffle plate where the first phase and second phase collection cells are located respectively, said longitudinal baffle plate is provided with a first and a second phase guiding holes in communication with the first phase and the second collection cells respectively.
    Type: Application
    Filed: August 15, 2018
    Publication date: February 21, 2019
    Applicants: China Petroleum & Chemical Corporation, Sinopec Exploration & Production Research Institue
    Inventors: Changchao Hu, Wei Dang, Xiaoxuan Xu, Zhiwei Tang, Lili Wang, Wenjie Tan, Pengyuan Ding, Caixia Bi, Youlin Zheng
  • Patent number: 10183999
    Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: January 22, 2019
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John Desjarlais, Stephen K. Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
  • Patent number: 10184000
    Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: January 22, 2019
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John Desjarlais, Stephen K. Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
  • Publication number: 20180360981
    Abstract: The present invention relates to Fc variants with optimized Fc ligand binding properties, methods for their generation, Fc polypeptides comprising Fc variants with optimized Fc ligand binding properties, and methods for using same.
    Type: Application
    Filed: January 29, 2018
    Publication date: December 20, 2018
    Inventors: Gregory Alan Lazar, Bassil Dahiyat, Wei Dang, John Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
  • Patent number: 10113001
    Abstract: The present invention relates to Fc variants having increased affinity for Fc?RIIc, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: October 30, 2018
    Assignee: Xencor, Inc.
    Inventors: Gregory Lazar, Wei Dang, John Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes